Important role and mechanism of lipid metabolism in breast cancer progression

doi:10.3760/cma.j.issn.1007-1245.2024.15.002

Abstract

Abstract:

Breast cancer is a malignant tumor originating from breast epithelial tissue, and its incidence rate is increasing year by year. Studies have shown that the level and regulation of lipid metabolism play an important role in the tumor cell proliferation, migration, invasion, metastasis, and development of drug resistance. This paper reviews the role and mechanism of lipid metabolism in the breast cancer progression from three aspects: lipid metabolism components (fatty acids, triglycerides and cholesterol), lipid metabolism signaling pathway, and regulatory genes of lipid metabolism, offers insights into the potential clinical value of targeted lipid metabolism therapy, and provides theoretical references for formulating effective treatment strategies and developing metabolism-targeted drugs.

Key words:

Breast cancer, Lipid metabolism, Signaling pathways, Regulatory genes, Mechanism of action, Progress

摘要：

乳腺癌是起源于乳腺上皮组织的恶性肿瘤，其发病率呈逐年上升趋势。脂质代谢水平和调控作用在肿瘤细胞的增殖、迁移、侵袭、转移和产生耐药性的过程中发挥重要作用。本文从脂质代谢成分（包括脂肪酸、三酰甘油和胆固醇）、脂质代谢信号通路、脂质代谢调控基因3个方面，综述脂质代谢在乳腺癌进展过程中的作用与机制，展望靶向脂质代谢治疗的潜在临床价值，为制定有效的治疗策略和开发代谢靶向药物提供理论参考。

关键词:

乳腺癌, 脂质代谢, 信号通路, 调控基因, 作用机制, 进展

Cai Yiwei, Yan Chenming, Yue Linhao, Wang Xiaohong, Jia Zhongming.

Important role and mechanism of lipid metabolism in breast cancer progression [J]. International Medicine and Health Guidance News, 2024, 30(15): 2470-2473.

蔡艺威闫晨名岳林皓王晓红贾中明.

脂质代谢在乳腺癌进展过程中的重要作用与机制 [J]. 国际医药卫生导报, 2024, 30(15): 2470-2473.

References

[1] Barzaman K, Karami J, Zarei Z, et al. Breast cancer: biology, biomarkers, and treatments[J]. Int Immunopharmacol, 2020,84:106535. DOI: 10.1016/j.intimp.2020.106535.
[2] 雷雨蒙,王钦,易玲娜,等. 武汉市社区适龄女性乳腺癌认知度与乳腺自检现状调查[J]. 公共卫生与预防医学,2019,30(3):103-106. DOI:10.3969/j.issn.1006-2483. 2019.03.024.
[3] Hultsch S, Kankainen M, Paavolainen L, et al. Association of tamoxifen resistance and lipid reprogramming in breast cancer[J]. BMC Cancer, 2018,18(1):850. DOI: 10.1186/s12885-018-4757-z.
[4] Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer[J]. Nat Rev Cancer, 2016,16(11):732-749. DOI: 10.1038/nrc.2016.89.
[5] Song L, Liu Z, Hu HH, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy[J]. Nat Commun, 2020,11(1):5842. DOI: 10.1038/s41467-020- 19694-w.
[6] 沈俊俊,潘月芬,钟丽萍,等. 浸润性乳腺癌的血脂代谢特点及其与分子分型的关系研究[J]. 中国卫生检验杂志,2018,28(19):2352-2355,2358.
[7] Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea[J]. J Clin Oncol, 2011,29(12):1592-1598. DOI: 10.1200/JCO.2010.31.5200.
[8] 蒋圣早,陈东祥.血清血脂及载脂蛋白水平与乳腺癌的相关性[J].中国现代医生,2015,53(14):17-20.
[9] 姚宇锋,唐金海,秦建伟. 脂质代谢紊乱对乳腺癌复发转移的影响[J]. 现代肿瘤医学,2011,19(12):2454-2455. DOI:10.3969/j.issn.1672-4992.2011.12.29.
[10] Li P, Lu M, Shi J, et al. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis[J]. Nat Immunol, 2020,21(11):1444-1455. DOI: 10.1038/s41590-020-0783-5.
[11] 黄赞. 脂质代谢、体质量指数与乳腺癌发生的关系[J]. 中国实用医药,2019,14(27):3-5. DOI:10.14163/j.cnki. 11-5547/r.2019.27.002.
[12] Li X, Liu ZL, Wu YT, et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy[J]. Lipids Health Dis, 2018,17(1):91. DOI: 10.1186/s12944-018-0745-1.
[13] Nelson ER. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer[J]. Mol Cell Endocrinol, 2018,466:73-80. DOI: 10.1016/j.mce.2017.09.021.
[14] Zhao Z, Hao D, Wang L, et al. CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-β signaling[J]. Oncogene, 2019,38(12):2076-2091. DOI: 10.1038/s41388-018-0570-z.
[15] 陈妮娜,赵磊,曹邦伟. 胆固醇——乳腺癌风险和预后的预测因子[J]. 肿瘤防治研究,2019,46(9):847-850. DOI:10.3971/j.issn.1000-8578.2019.19.0265.
[16] Gallagher EJ, Zelenko Z, Neel BA, et al. Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia[J]. Oncogene, 2017,36(46):6462-6471. DOI: 10.1038/onc.2017.247.
[17] 谢钰德,李志升,李圆,等. 脂肪酸合成酶在乳腺癌治疗抵抗中的研究进展[J]. 广东医学,2023,44(4):519-524. DOI:10.13820/j.cnki.gdyx.20223289.
[18] Nieman KM, Romero IL, Van Houten B, et al. Adipose tissue and adipocytes support tumorigenesis and metastasis[J]. Biochim Biophys Acta, 2013,1831(10):1533-1541. DOI: 10.1016/j.bbalip.2013.02.010.
[19] Luo DX, Tong DJ, Rajput S, et al. Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential[J]. Recent Pat Anticancer Drug Discov, 2012,7(2):168-84. DOI: 10.2174/157489212799972918.
[20] 王淼,王欣宇,李鸿铭,等. 脂质代谢在乳腺癌发病中的作用[J]. 生物化学与生物物理进展,2022,49(6):1052-1060. DOI:10.16476/j.pibb.2021.0123.
[21] Gruslova A, McClellan B, Balinda HU, et al. FASN inhibition as a potential treatment for endocrine-resistant breast cancer[J]. Breast Cancer Res Treat, 2021,187(2):375-386. DOI: 10.1007/s10549-021-06231-6.
[22] Rysman E, Brusselmans K, Scheys K, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation[J]. Cancer Res, 2010,70(20):8117-8126. DOI: 10.1158/0008-5472.CAN-09-3871.
[23] 程丽,马颖超,谢富华. 脂肪酸代谢失调影响乳腺癌发展[J]. 赣南医学院学报,2023,43(6):570-576. DOI:10.3969/j.issn.1001-5779.2023.06.004.
[24] 曹林,韩丽,杨明,等. 利用生物信息学分析筛选乳腺癌不良预后的关键基因[J]. 中国医药生物技术,2020,15(4):404-410. DOI:10.3969/j.issn.1673-713X.2020.04.012.
[25] Zhao D, Mo Y, Li MT, et al. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells[J]. J Clin Invest, 2014,124(12):5453-5465. DOI: 10.1172/JCI76611.
[26] Chen M, Lu P, Ma Q, et al. CTNNB1/β-catenin dysfunction contributes to adiposity by regulating the cross-talk of mature adipocytes and preadipocytes[J]. Sci Adv, 2020,6(2):eaax9605. DOI: 10.1126/sciadv.aax9605.
[27] 臧传鑫,刘瑞娟,赵文歌,等. 乳腺癌干细胞相关信号通路及其抑制剂的研究进展[J]. 肿瘤学杂志,2019,25(1):27-31. DOI:10.11735/j.issn.1671-170X.2019.01.B007.
[28] Porstmann T, Santos CR, Griffiths B, et al. A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth[J]. Cell Metab, 2008,8(3):224-236. DOI: 10.1016/j.cmet.2008.07.007.
[29] 许光亚,王婷,李斌,等. 乳腺癌的靶向治疗研究进展[J]. 中国药物经济学,2021,16(9):125-128. DOI:10.12010/j.issn. 1673-5846.2021.09.027.
[30] Little JL, Wheeler FB, Fels DR, et al. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells[J]. Cancer Res, 2007,67(3):1262-1269. DOI: 10.1158/0008-5472.CAN-06-1794.
[31] Wu X, Qin L, Fako V, et al. Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments[J]. Adv Biol Regul, 2014,54:214-221. DOI: 10.1016/j.jbior.2013.09.004.
[32] Giró-Perafita A, Palomeras S, Lum DH, et al. Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer[J]. Clin Cancer Res, 2016,22(18):4687-4697. DOI: 10.1158/1078-0432.CCR-15- 3133.
[33] 吕静,王斌,糜漫天,等.脂质代谢相关基因在乳腺浸润性导管癌中的表达及其意义[J].第三军医大学学报,2010,32(12):1290-1292.DOI:10.16016/j.1000-5404.2010. 12.030.
[34] Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins[J]. Oncogene, 2012,31(48):4967-4978. DOI: 10.1038/onc.2012.6.
[35] Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial[J]. Breast Cancer Res Treat, 2013,138(2):499-508. DOI: 10.1007/s10549-013-2473-6.